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In the course of apoptosis, activated caspases cleave ∼500 to
∼1,000 different proteins in a mammalian cell. The dynamics of
apoptosis involve a number of previously identiﬁed, caspase-gen-
erated proapoptotic protein fragments, deﬁned as those that in-
crease the probability of apoptosis. In contrast to activated
caspases, which can be counteracted by inhibitor of apoptosis
proteins, there is little understanding of antiapoptotic responses
to proapoptotic protein fragments. One possibility is the regula-
tion of proapoptotic fragments through their selective degrada-
tion. The previously identiﬁed proapoptotic fragments Cys-RIPK1,
Cys-TRAF1, Asp-BRCA1, Leu-LIMK1, Tyr-NEDD9, Arg-BID, Asp-
BCLXL, Arg-BIMEL, Asp-EPHA4, and Tyr-MET bear destabilizing N-
terminal residues. Tellingly, the destabilizing nature (but not nec-
essarily the actual identity) of N-terminal residues of proapoptotic
fragments was invariably conserved in evolution. Here, we show
that these proapoptotic fragments are short-lived substrates of
the Arg/N-end rule pathway. Metabolic stabilization of at least
one such fragment, Cys-RIPK1, greatly augmented the activation
of the apoptosis-inducing effector caspase-3. In agreement with
this understanding, even a partial ablation of the Arg/N-end rule
pathway in two speciﬁc N-end rule mutants is shown to sensitize
cells to apoptosis. We also found that caspases can inactivate com-
ponents of the Arg/N-end rule pathway, suggesting a mutual sup-
pression between this pathway and proapoptotic signaling.
Together, these results identify a mechanistically speciﬁc and func-
tionally broad antiapoptotic role of the Arg/N-end rule pathway.
In conjunction with other apoptosis-suppressing circuits, the Arg/
N-end rule pathway contributes to thresholds that prevent a tran-
sient or otherwise weak proapoptotic signal from reaching the
point of commitment to apoptosis.
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Perturbations of apoptosis, a speciﬁc kind of programmed celldeath, play major roles in human diseases, including cancer,
disorders of immunity, and neurodegenerative syndromes. Ap-
optosis is mediated by proteases called caspases, which are ac-
tivated in response to extracellular signals or upon intracellular
stresses (reviewed in refs. 1–12). Apoptosis involves the activa-
tion of initiator caspases (e.g., caspase-8). This and other initi-
ator caspases cleave and activate effector caspases, including
caspase-3. By making sequence-speciﬁc cuts in many cellular
proteins, caspases either abolish or alter the functions of these
proteins (13, 14). Activation of caspases can result in death of
a cell, cell differentiation, or other effects, depending on physi-
ological context (2, 3, 5).
After induction of apoptosis in a mammalian cell, ∼500 to
∼1,000 different proteins are cleaved by caspases (4, 5, 8). A
small but biologically signiﬁcant subset of the resulting fragments
comprises polypeptides with proapoptotic activity. Such frag-
ments are deﬁned, operationally, as those that can be shown to
increase the probability of apoptosis compared with full-length
precursors of these fragments. Previous studies identiﬁed about
20 proapoptotic fragments of mammalian proteins (references in
SI Results and SI Materials and Methods). In contrast to activated
caspases, which can be counteracted by inhibitor of apoptosis
(IAP) proteins (15, 16), there is little understanding of anti-
apoptotic responses to caspase-generated proapoptotic frag-
ments. We report here that the Arg/N-end rule pathway down-
regulates a number of proapoptotic fragments through their
selective degradation.
The N-end rule relates the in vivo half-life of a protein to the
identity of its N-terminal residue. Regulated degradation of
speciﬁc proteins by the N-end rule pathway mediates a number
of functions, including the sensing of heme, nitric oxide, and
oxygen; elimination of misfolded proteins; signaling by G pro-
teins; and regulation of peptide import, DNA repair, chromo-
some cohesion/segregation, fat metabolism, spermatogenesis,
neurogenesis, cardiovascular development, and many processes
in plants (reviewed in refs. 17–22). The N-end rule pathway
polyubiquitylates proteins that contain speciﬁc degradation sig-
nals (degrons), thereby targeting these proteins for degradation
by the 26S proteasome. Degrons recognized by the N-end rule
pathway include a set called N-degrons. The main determinant
of an N-degron is a destabilizing N-terminal residue of a sub-
strate protein. Recognition components of the N-end rule
pathway, called N-recognins, are speciﬁc E3 Ub ligases that can
target N-degrons (17, 23). The N-end rule pathway consists of
two branches, the Ac/N-end rule and the Arg/N-end rule path-
ways. The Ac/N-end rule pathway recognizes proteins with N-
terminally acetylated residues (24). The Arg/N-end rule pathway
targets speciﬁc unacetylated N-terminal residues (Fig. 1A) (17,
25). The primary destabilizing N-terminal residues Arg, Lys,
His, Leu, Phe, Tyr, Trp, and Ile are directly recognized by E3
N-recognins, whereas N-terminal Asp, Glu, Asn, Gln, and Cys
function as destabilizing residues through their preliminary mod-
iﬁcations. These modiﬁcations include N-terminal arginylation
(Nt-arginylation) by the ATE1 arginyl-transferase (R-transferase)
(Fig. 1A) (17, 26–30).
Because cleavage sites in proteins that give rise to proapoptotic
fragments coevolved with other elements of proapoptotic and
antiapoptotic circuits, one possibility is that proapoptotic protein
fragments are regulated through their selective degradation. In-
deed, as shown below, at least 10 of the previously identiﬁed
proapoptotic fragments are short-lived substrates of the Arg/N-end
rule pathway. Metabolic stabilization of at least one such fragment
was found to greatly augment the activation of the apoptosis-in-
ducing effector caspase-3. In agreement with this understanding,
even a partial ablation of the Arg/N-end rule pathway is shown to
make cells hypersensitive to apoptosis. We also found that caspases
can cleave and inactivate components of the Arg/N-end rule
pathway, suggesting a mutual suppression between the Arg/N-end
rule and proapoptotic signaling. Together, these results identiﬁed
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a mechanistically speciﬁc and functionally broad antiapoptotic role
of the Arg/N-end rule pathway.
Results
Conservation of Destabilizing N-Terminal Residues in Proapoptotic
Fragments. By surveying the literature for the previously identi-
ﬁed proapoptotic mammalian protein fragments, we found that,
of 20 such fragments, 16 of them bear N-terminal residues that
are destabilizing in the Arg/N-end rule pathway (Fig. 1A and Fig.
S1). These N-terminal residues have been unambiguously map-
ped in studies cited in SI Results. None of these studies consid-
ered a possible regulation of proapoptotic fragments by the Arg/
N-end rule pathway.
We also found that the N-terminal residues of these proa-
poptotic fragments (they are P1′ residues in the cleavage sites of
the full-length precursors) were conserved among vertebrates
(Figs. S1 and S2), with one seeming exception: the P1′ residue of
the caspase cleavage site in the tumor suppressor BRCA1 is Asp
in humans and mice but Ile in water mice, Glu in rabbits, and
Asn in bats (Fig. S2C). Tellingly, however, all of these P1′ resi-
dues of BRCA1 in different mammals are destabilizing in the
Arg/N-end rule (Fig. 1A and Fig. S2C). A constraint of this kind
would be expected if a short in vivo half-life of the proapoptotic
fragment (rather than the exact identity of its N-terminal residue)
was a ﬁtness-increasing property of this fragment maintained by
selection during evolution. The retention of destabilizing P1′
residues in the precursors of proapoptotic fragments (Figs. S1 and
S2) is noteworthy for another reason as well. More than 90% of
the mapped caspase cleavage sites in cellular proteins contain, at
their P1′ positions, small residues such as Gly, Ser, Thr, and Ala
Fig. 1. Partial ablations of the Arg/N-end rule pathway sensitize cells to apoptosis. (A) The mammalian Arg/N-end rule pathway (17). N-terminal residues are
indicated by single-letter abbreviations for amino acids. Yellow ovals denote the rest of a protein substrate. Primary, secondary, and tertiary denote
mechanistically distinct subsets of destabilizing N-terminal residues. C* denotes oxidized N-terminal Cys (either Cys-sulﬁnate or Cys-sulfonate). (B) Percentage
of apoptotic (TUNEL-positive) cells produced by UV irradiation in WT, Ate1−/−, and Ubr1−/− Ubr2−/−mouse EF cell lines (◆,■, and●, respectively). (C) Same as
B but for induction of apoptosis by staurosporine. (D) Same as B but for the colony-forming ability of treated cells. (E) Percentage of TUNEL-positive cells in
the lungs and pancreases of ATE1-containing and -deﬁcient mice that had been treated with TNFα (Fig. S4); ∼30,000 cells in lung and ∼15,000 cells in pancreas
were scored for TUNEL-positive cells vs. total (DAPI-stained) cells. SEMs are indicated. Statistical analyses were performed using the t test (P < 0.0001 for lung,
P < 0.00004 for pancreas).
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(4, 8). These residues are not recognized by the Arg/N-end rule
pathway (Fig. 1A). Thus, remarkably, the destabilizing P1′ resi-
dues in the precursors of proapoptotic fragments (let alone the
evolutionary conservation of these residues) (Figs. S1 and S2)
would not be expected on a priori grounds given the pre-
ponderance of smaller P1′ residues in caspase substrates at large
(4, 8). Together, these ﬁndings (Figs. S1 and S2) strongly sug-
gested adaptive (ﬁtness-increasing) origins of destabilizing P1′
residues in the precursors of proapoptotic fragments.
Proapoptotic Fragments as Short-Lived Arg/N-End Rule Substrates.
The initial uncertainty about whether a protein with a destabi-
lizing N-terminal residue is an efﬁcacious substrate of the Arg/N-
end rule pathway stems from the multideterminant organization
of an N-degron. This degradation signal must contain not only a
sterically accessible destabilizing N-terminal residue but also a
suitably located disordered segment of a target protein and
a ubiquitylatable internal Lys residue (17).
To determine whether the proapoptotic fragments (Fig. S1)
were, in fact, degraded by the Arg/N-end rule pathway, we used
the extensively validated Ub reference technique (URT) derived
from the Ub fusion technique (17, 31, 32). Cotranslational
cleavage of a URT-based Ub fusion by deubiquitylases produces,
at the initial equimolar ratio, both a test protein with a desired
N-terminal residue and a reference fDHFR-UbR48, a ﬂag-tagged
derivative of the mouse dihydrofolate reductase (Fig. 2A). In
URT-based pulse-chase assays, the labeled test protein is
quantiﬁed by measuring its levels relative to the levels of a stable
reference at the same time point during a chase (Fig. 2A). In
addition to being more accurate than pulse-chases without a
built-in stable reference, URT makes it possible to measure the
degradation of the test protein before the chase (i.e., during the
pulse) (24, 31, 32).
URT-based 35S-pulse chases with 10 proapoptotic fragments
were performed in a transcription-enabled rabbit reticulocyte
extract, which contains the Arg/N-end rule pathway and has been
extensively used to analyze this pathway (Figs. 1A, 2, and 3 and
Fig. 2. Cys-RIPK1, Cys-TRAF1, Asp-BRCA1, Leu-LIMK1, and Tyr-NEDD9 as short-lived N-end rule substrates. Molecular masses of the test proteins were ∼1 kDa
larger than their indicated (natural) sizes, because these fragments contained the ∼1 kDa ﬂag epitope. (A) The URT assay (31, 32). (B) The caspase cleavage site
in mouse RIPK1 is indicated by an arrowhead, with the P1′ residue shown in red. Residue numbers are the numbers of the ﬁrst shown residue and the last
residue of full-length RIPK1. Cys326-RIPK1f (produced from fDHFR-UbR48-Cys326-RIPK1f) and Val326-RIPK1f were expressed in reticulocyte extract and labeled
with 35S-Met/Cys for 10 min at 30 °C, followed by a chase, immunoprecipitation with anti-ﬂag antibody, SDS/PAGE, and autoradiography. (C) Quantiﬁcation
of B using the reference protein fDHFR-UbR48. (D) Same as B but with mouse X157-TRAF1f (X = Cys, Met). In these pulse chases, the reference was ﬂag-tagged
fUbR48 instead of fDHFR-UbR48. (E) Quantiﬁcation of D. (F) Same as in B but with mouse X1119-BRCA1f (X = Asp, Val). (G) Quantiﬁcation of F. (H) Same as in B
but with human X241-LIMK1f (X = Leu, Val). (I) Quantiﬁcation of H. (J) Same as in B but with human X631-NEDD9f (X = Tyr, Val). (K) Quantiﬁcation of J [◆,
a natural proapoptotic fragment; ■, an otherwise identical fragment with N-terminal Val (or Met in D and E)].














Fig. S1) (17). All of the examined proapoptotic fragments have
been shown to be generated in vivo by activated caspases except
for Arg71-BID and Asp61-BCLXL, which are produced by acti-
vated calpains during cell death mediated by an increase in Ca2+
(Fig. S1). Speciﬁc URT fusions (Fig. 2A) C-terminally tagged
with the ﬂag epitope were labeled with 35S-Met/Cys in re-
ticulocyte extract for 10 min at 30 °C, followed by a chase, im-
munoprecipitation with a monoclonal anti-ﬂag antibody, SDS/
PAGE, autoradiography, and quantiﬁcation (Figs. 2 and 3). The
logic of these assays (17) involves a comparison between the
degradation rates of a protein bearing a destabilizing N-terminal
residue and an otherwise identical protein with an N-terminal
residue such as Val, which is not recognized by the Arg/N-end
rule pathway (Fig. 1A).
Brief descriptions of the 10 proapoptotic fragments below
(Figs. 2 and 3) are complemented by the detailed references and
descriptions in SI Results. The proapoptotic fragments Cys326-
RIPK1 (its precursor is a protein kinase and regulator of apo-
ptosis), Asp1119-BRCA1 (its precursor is an E3 Ub ligase and
a tumor suppressor), Leu241-LIMK1 (its precursor is a protein
kinase), Tyr631-NEDD9 (its precursor is a scaffolding protein),
Asp61-BCLXL (its precursor is an antiapoptotic protein), Arg
14-
BIMEL (its precursor is a regulator of apoptosis), and Tyr
1001-
MET (its precursor is a dependence receptor) were short-lived in
reticulocyte extract, whereas the otherwise identical fragments
bearing the N-terminal Val residue (which is not recognized by
the Arg/N-end rule pathway) were either stable or nearly stable
(Figs. 2 and 3). These results indicated that the seven cited
Fig. 3. Arg-BID, Asp-BCLXL, Arg-BIMEL, Asp-EPHA4, and Tyr-MET as short-lived N-end rule substrates. (A) Human Arg
71-BIDf (produced from fDHFR-UbR48-
Arg71-BIDf), the otherwise identical Val71-BIDf, and the calpain cleavage site in BID. Fig. 2 shows notations and pulse-chase procedures. (B) Quantiﬁcation of A.
(C) Same as in A but with mouse X61-BCLXL
f (X = Asp, Val). (D) Quantiﬁcation of C. (E) Same as in A but with mouse X14-BIMEL
f (X = Arg, Val). (F) Quantiﬁcation
of E. (G) Same as in A but with mouse X774-EPHA4f (X = Asp, Val). (H) Quantiﬁcation of G. (I) Same as in A but with mouse X1001-METf (X = Tyr, Val). (J)
Quantiﬁcation of I. (K) Cleavage of RIPK1 by caspase-8. Mouse RIPK1ha was expressed in reticulocyte extract for 45 min at 30 °C, followed by the addition of
cycloheximide and either recombinant human caspase-8 or buffer alone. The samples were incubated for 30 min followed by SDS/PAGE and immunoblotting
with anti-ha antibody. Lane 1, RIPK1ha; lanes 2 and 3, same as lane 1 but with the Arg-Ala and Ala-Arg, respectively, at 5 mM added the start of assays; lanes
4–6, same as lanes 1–3, respectively, but with caspase-8 as well. Note the caspase-generated C-terminal RIPK1 fragment migrating at the Mr of the 41-kDa
Cys326-RIPK1ha in lane 5 (with 5 mM Arg-Ala) but not in lane 4 (no added dipeptide) or lane 6 (with 5 mM Ala-Arg). (L) Cleavage of TRAF1 by caspase-8. Mouse
TRAF1f and its caspase-resistant mutant TRAF1D156A(f) were expressed in reticulocyte extract for 1 h at 30 °C in the presence of [35S]methionine, followed by the
addition of cycloheximide, unlabeled methionine and cysteine, and either caspase-8 or buffer alone. Samples were incubated for another 30 min, followed by
SDS/PAGE and autoradiography. Lanes 1 and 3, TRAF1f and TRAF1D156A(f), respectively; lanes 2 and 4, same as lanes 1 and 3, respectively, but with caspase-8.
Note the much lower (degradation-mediated) level of the 35S-labeled, caspase-generated C-terminal TRAF1 fragment denoted as Ct-TRAF1f (it migrates at the
expected Mr of the Cys
157-TRAF1 fragment) compared with the N-terminal fragment (denoted as Nt-TRAF1f), despite the higher content of 35S-Met in Ct-TRAF1f.
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proapoptotic fragments contained Arg/N-degrons and further-
more, that their Arg/N-degrons were either the sole or major
degradation signals in these proteins. Similarly, the proapoptotic
fragments Cys157-TRAF1 (its precursor is a regulator of apo-
ptosis), Arg71-BID (its precursor is proapoptotic as well but less
than Arg71-BID), and Asp774-EPHA4 (its precursor is a de-
pendence receptor) were also short-lived in reticulocyte extract.
Their counterparts bearing N-terminal Val (or Met in the case of
X157-TRAF1) were considerably longer lived but still unstable,
indicating the presence of both Arg/N-degrons and internal
degrons in these three proapoptotic fragments (Figs. 2 and 3).
In sum, we examined 10 of 16 proapoptotic fragments as possible
Arg/N-end rule substrates (Fig. S1) and found that all 10 of them
were, in fact, short-lived substrates of the Arg/N-end rule pathway
(Figs. 2 and 3). In amajority of these fragments, theirArg/N-degrons
were their sole degrons at least in reticulocyte extract.
Stabilization of the Cys-RIPK1 Proapoptotic Fragment Greatly
Augments the Activation of Apoptosis-Inducing Caspase-3. The hu-
man Cys325-RIPK1 fragment was a short-lived Arg/N-end rule
substrate both in reticulocyte extract (Fig. 2 B and C) (half-life of
∼20 min) and T-Rex-293 human cells (Fig. S3 A and B) (initial
half-life of ∼15 min). These cell lines were designed to stably
express either Cys325-RIPK1 or Val325-RIPK1 using a doxycy-
cline (Dox)-inducible promoter and site-speciﬁc integration of
transgenes. In contrast to the short-lived mouse or human Cys-
RIPK1 fragment, the otherwise identical Val-RIPK1 was either
stable (in reticulocyte extract) (Fig. 2 B and C) or degraded at
a much lower rate (in T-Rex-293 cells) (Fig. S3 A and B).
The proapoptotic activity of the Cys325-RIPK1 fragment
involves the promotion of activation of the initiator caspase-8
(33). One role of caspase-8 is the activation of the effector cas-
pase-3, a major step to apoptosis (5). Although both the short-
lived Cys325-RIPK1f fragment and the otherwise identical long-
lived Val325-RIPK1f could be observed to activate caspase-3 in
T-Rex-293 cells, the levels of caspase-3 activation were strikingly
higher in cells that expressed the long-lived Val325-RIPK1 (Fig.
4A). Assays identical to the ones in Fig. 4A but with measure-
ments of overtly apoptotic cells (instead of activated caspase-3)
indicated a greatly increased proapoptotic activity of the stabi-
lized Val325-RIPK1f fragment compared with its short-lived
Cys325-RIPK1f counterpart.
To assess the previously shown production of the proapoptotic
Cys-RIPK1 fragment by caspase-8 (33–35), the full-length,
C-terminally ha-tagged mouse RIPK1ha was expressed in re-
ticulocyte extract in the presence or absence of active caspase-8.
Degradation of Arg/N-end rule substrates can be selectively
inhibited by dipeptides such as Arg-Ala and Leu-Ala, which bear
type 1 (basic) or type 2 (bulky hydrophobic) destabilizing N-
terminal residues, respectively, and interact with type 1/2 sub-
strate-binding sites of N-recognins (Fig. 1A) (17). In the absence
of caspase-8, RIPK1ha remained intact (Fig. 3K, lanes 1–3). In
contrast, virtually no RIPK1ha was retained in the presence of
caspase-8 (Fig. 3K, lane 4 compared with lanes 1–3) because of
the formation of the Cys326-RIPK1ha fragment (33–35) and its
degradation by the Arg/N-end rule pathway (Fig. 2 B and C). As
would be expected, the addition of the Arg-Ala (but not the Ala-
Arg) dipeptide to reticulocyte extract partially stabilized a C-
terminal fragment of RIPK1 that migrated at the Mr of Cys
326-
RIPK1ha (Fig. 3K, lane 5 compared with lanes 4 and 6).
In Vivo Stabilization of the Asp-BRCA1 Fragment in the Absence of
Arginylation. Mouse BRCA1, an E3 Ub ligase and a tumor sup-
pressor, is cleaved by caspases during apoptosis, resulting in the
proapoptotic 78-kDa Asp1119-BRCA1 fragment (SI Results and
Figs. S1 and S2C). Similarly to several other proapoptotic Arg/
N-end rule substrates (Fig. S1), the degradation of Asp1119-
BRCA1 requires its preliminary Nt-arginylation by the ATE1
R-transferase (Fig. 1A). The half-life of Asp1119-BRCA1 in re-
ticulocyte extract was ∼6 min, whereas Val1119-BRCA1 was
stable (Fig. 2 F and G).
In contrast to functionally overlapping E3 N-recognins of the
mammalian Arg/N-end rule pathway (Fig. 1A), the upstream
R-transferase is encoded by a single Ate1 gene. Taking advantage
of this fact, we asked whether caspase-mediated production of
Asp1119-BRCA1 from endogenous BRCA1 in living cells is ac-
companied by degradation of this fragment by the Arg/N-end
rule pathway. A mouse embryonic ﬁbroblast (EF) cell line and its
Ate1−/− counterpart that lacked Nt-arginylation (Fig. 1A) (17, 26)
were treated with apoptosis-inducing UV irradiation, followed by
incubation for 4 h and labeling with [35S]methionine/cysteine for
60 min. Caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK
(the latter is a pan-caspase inhibitor) were then added, followed
by a chase, immunoprecipitation of cell extracts with antibody to
BRCA1, SDS/PAGE, and autoradiography (Fig. 4 C and D).
Caspase inhibitors were added to halt the production of Asp1119-
BRCA1 from BRCA1, so that the 35S-labeled Asp1119-BRCA1
fragment could be followed during chase.
The bulk of the 199-kDa BRCA1 was cleaved or otherwise
degraded after UV irradiation (Fig. 4C, lane 1 compared with
lanes 2–7). The previously identiﬁed endogenous Asp1119-
BRCA1 fragment (SI Results) migrated at the expected Mr and
was present at the beginning of chase in both Ate1−/− and WT EF
cells (Fig. 4C). However, the prechase levels of Asp1119-BRCA1
were reproducibly approximately twofold higher in Ate1−/− cells,
suggesting a signiﬁcant degradation of Asp1119-BRCA1 during
35S-labeling in WT cells (Fig. 4 C and D). Moreover, whereas
35S-labeled Asp1119-BRCA1 was short-lived in WT cells during
the chase (half-life of ∼25 min), it was stable in Ate1−/− cells,
which lacked Nt-arginylation (Fig. 4 C and D).
In another approach, we prepared a rabbit antibody to
RDVEIQGHTSFC, the Nt-arginylated N-terminal sequence of
the Asp1119-BRCA1 fragment (except for C-terminal Cys, which
was used to conjugate peptide to a carrier protein). This antibody
was afﬁnity-puriﬁed both positively (against RDVEIQGHTSFC)
and negatively (against DVEIQGHTSFC). The resulting anti-
body exhibited a striking speciﬁcity for the Nt-arginylated
RDVEIQGHTSFC peptide (Fig. 4F). Immunoblotting extracts
of WT, Ate1−/−, and double-mutant Ubr1−/− Ubr2−/− EF cells
with this antibody produced results in agreement with pulse-
chase ﬁndings (Fig. 4 C and D). Speciﬁcally, whereas virtually
no Arg-Asp1119-BRCA1 fragment was detectable in untreated
WT EF cells, apoptosis-inducing UV irradiation of these cells
resulted in a detectable level of the (short-lived) Arg-Asp1119-
BRCA1 fragment, with an additional (expected) increase of this
fragment in the presence of MG132, a proteasome inhibitor (Fig.
4E, lanes 1–3). In contrast and in agreement with speciﬁcity of
this antibody, no Arg-Asp1119-BRCA1 could be detected in
extracts of Ate1−/− EF cells (which lacked Nt-arginylation) under
any conditions (Fig. 4E, lanes 4–6), although the Asp1119-
BRCA1 fragment was present in these cells after UV irradiation,
which could be seen using a pan-BRCA1 antibody (Fig. 4C). The
results with Ubr1−/− Ubr2−/− EF cells, which lacked two of four
E3 Ub ligases of the Arg/N-end rule pathway and retained Nt-
arginylation (Fig. 1A), were qualitatively similar to the results
with WT EF cells (Fig. 4E, lanes 7–9).
We conclude that, despite signiﬁcant differences in the mo-
lecular environment (Asp1119-BRCA1 in reticulocyte extract vs.
endogenous Asp1119-BRCA1 in apoptotic mouse cells), the ki-
netics of cleavage that generate Asp1119-BRCA1 (cotranslational
vs. posttranslational), and the nature of proteases involved
(deubiquitylases vs. caspases), the Asp1119-BRCA1 fragment was
a short-lived Arg/N-end rule substrate in either the heterologous
or natural setting (Figs. 2 F and G and 4 C and D).














Partial Ablations of the Arg/N-End Rule Pathway Make Cells
Hypersensitive to Apoptosis. If the degradation of proapoptotic
protein fragments counteracts cell death, even a partial stabili-
zation of these fragments would be expected to increase the
sensitivity of cells to apoptosis. One line of evidence of this kind,
described above, was a greatly increased proapoptotic activity of
a metabolically stabilized derivative of the proapoptotic Cys325-
RIPK1 fragment (Fig. 4A).
Of the 10 proapoptotic fragments identiﬁed here as Arg/N-end
rule substrates, 5 fragments (Asp-BRCA1, Cys-RIPK1, Cys-
TRAF1, Asp-BCLXL, and Asp-EPHA4) are targeted for degra-
dation through their Nt-arginylation (Figs. 1A, 2, 3, and 4 and
Figs. S1, S2, and S3). An Ate1−/− EF cell line, which lacked Nt-
arginylation (26), was indeed hypersensitive to apoptosis induced
by either UV irradiation or staurosporine, a kinase inhibitor
known to induce apoptosis (Fig. 1 B–D). The hypersensitivity of
Ate1−/− cells to apoptosis was detected using either the TUNEL
assay for fragmented DNA (Fig. 1 B and C) or a growth assay for
the ability of treated cells to form colonies (Fig. 1D). To pre-
clude the possibility that other, non-Ate1 mutations in these
Ate1−/− cells might underlie the observed phenotype, we re-
peated the above experiments (Fig. 1 B–D) with a second Ate1−/−
EF cell line produced from independently derived Ate1−/− em-
bryos and obtained the same results. In addition and also im-
portantly, primary early-passage (nontransformed) Ate1−/− EF
cells were similar to the postcrisis Ate1−/− cell lines in their hy-
persensitivity to apoptosis (Fig. 1 B–D compared with Fig. S3C).
We also examined a Ubr1−/− Ubr2−/− EF cell line, which retained
Nt-arginylation but had a weakened Arg/N-end rule pathway
because of the ablation of two (of at least four) N-recognins (Fig.
1A) (17, 22). Similarly to Ate1−/− EFs (which lacked Nt-arginy-
lation but retained N-recognins), Ubr1−/− Ubr2−/− EFs were hy-
persensitive to apoptosis induced by either UV or staurosporine
(Fig. 1 B–D).
Together with the Cys/Val-RIPK1 metabolic stabilization
results (Fig. 4A), the ﬁndings with speciﬁc Arg/N-end rule
Fig. 4. Cys-RIPK1, Cys-BRCA1, ATE1, and the Arg/N-end rule pathway. (A) Activation of caspase-3 in human T-Rex-293–based cell lines stably expressing
human X325-RIPK1f fragments (X = Cys, Val) from a Dox-inducible promoter. Expression of X325-RIPK1f was induced with Dox over 24 h followed by the
addition of cycloheximide to a subtoxic (2.5 μg/mL) concentration, 12 h of additional incubation, and measurements, in triplicate, of caspase-3 activity in cell
extracts. SDs are indicated. Black bars, an integrated vector alone; blue bars, Cys325-RIPK1f; red bars, Val325-RIPK1f. (B) Functional inactivation of the ATE1
R-transferase by caspase-8. Puriﬁed mouse ATE1 (12.5 μg/mL) was treated with recombinant caspase-8 (0.1 μg/mL) or buffer alone for 30 min at 25 °C in the
presence or absence of the pan-caspase inhibitor Z-VAD-FMK. Reactions were stopped, followed by the addition of Glu-lactalbumin (an Nt-arginylation
reporter), 14C-L-arginine, and other components of ATE1 arginylation assay, incubation for 30 min at 30 °C, SDS/PAGE, and autoradiography (Upper). (Lower)
Bands of total lactalbumin stained with Ponceau-S. (C) WT and Ate1−/−mouse EF cell lines were UV-irradiated (60 J/m2), followed by incubation for 4 h and the
labeling of cells with 35S-Met/Cys for 60 min. Caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK, as well as unlabeled Met and Cys were then added, followed by
a chase, immunoprecipitation of cell extracts with antibody to BRCA1, SDS/PAGE, and autoradiography. (D) Quantiﬁcation of data in C.◆, Asp-BRCA1 in UV-
irradiated WT cells; ■, Asp-BRCA1 in UV-irradiated Ate1−/− cells. (E) Immunoblotting of mouse cell extracts with antibody to Arg-Asp1119-BRCA1 fragment.
Lanes 1–3, WT EF cells untreated, UV-irradiated, or UV-irradiated and treated with MG132; lanes 4–6, same as lanes 1–3 but with Ate1−/− EF cells; lanes 7–9,
same as lanes 1–3 but with Ubr1−/− Ubr2−/− EF cells. The band of Arg-Asp1119-BRCA1 is indicated. *A cross-reacting protein. (F) A dot blot assay for antibody to
the Arg-Asp1119-BRCA1 fragment. Indicated amounts of the RDVEIQGHTSFC or the DVEIQGHTSFC peptide were probed with the afﬁnity-puriﬁed antibody to
RDVEIQGHTSFC (in the text).
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mutants (Fig. 1 B–D) indicate that the Arg/N-end rule pathway is
a repressor of apoptosis, at least in part through its ability to
destroy proapoptotic fragments (Figs. 2 and 3). Importantly, the
apoptosis hypersensitivity of two distinct Arg/N-end rule mutants
was not accompanied by any increase of cell death (relative to
WT controls) in the absence of proapoptotic treatments.
Our previous work has produced Ate1ﬂox/- mouse strains in
which one copy of Ate1 was inactive, whereas the other (ﬂoxed)
copy of Ate1 could be inactivated in adult mice through a tran-
sient activation of Cre recombinase (30). The Cys-RIPK1 frag-
ment promotes apoptosis through a positive feedback that
facilitates the activation of caspase-8, which in turn, cleaves
RIPK1 to generate more Cys-RIPK1 (33–35). As shown here,
the Cys-RIPK1 fragment is a short-lived Arg/N-end rule sub-
strate that is targeted for degradation through Nt-arginylation
(Figs. 1A and 2 B and C and Figs. S1 and S2A). We compared
the levels of endogenous RIPK1 in ATE1-containing and ATE1-
deﬁcient mice that had been treated for 12 h with TNFα. A re-
markable all-or-none pattern was discovered in TNFα-responsive
tissues: whereas the levels of RIPK1 remained unchanged in the
lungs and pancreases of TNFα-treated ATE1-containing mice,
full-length RIPK1 virtually disappeared from identically treated
ATE1-deﬁcient mice (Fig. S4A, lanes 1–6 and 13–18). Similar
but not as striking patterns were observed with spleens (Fig. S4A,
lanes 7–12). No changes in RIPK1 were observed in the brains of
TNFα-treated mice of either genotype, presumably because of
the relative lack of TNFα access to the brain.
Although a RIPK1 fragment that migrated at the Mr of the
41-kDa Cys326-RIPK1 (Fig. 2 B and C and Fig. S2A) could be
detected in pancreases of TNFα-treated ATE1-deﬁcient mice,
the low level of this fragment suggested instability of Cys326-
RIPK1, even in ATE1-lacking cells (Fig. S4A, lanes 19 and 20
compared with lanes 17 and 18, which are the lower-exposure
counterparts of lanes 19 and 20). The presence of an internal
degron in Cys-RIPK1, in addition to its N-degron, was consistent
with residual instability of the human Val-RIPK1 fragment
(compared with Cys-RIPK1) in T-Rex-293 cells (Fig. S3B),
whereas only the Arg/N-degron of Cys-RIPK1 was active in re-
ticulocyte extract (Fig. 2 B and C). A mutually nonexclusive
possibility is that the absence of Nt-arginylation in ATE1-de-
ﬁcient mice not only augments the RIPK1/caspase-8 positive
feedback but also increases, through a mechanism to be un-
derstood, the TNFα-induced processive degradation of full-
length RIPK1, a conditionally short-lived protein (6, 33, 36). In
contrast to results with ATE1-deﬁcient mouse tissues (Fig. S4A),
a RIPK1 fragment that migrated at the Mr of the 41-kDa Cys
326-
RIPK1 was readily detectable in Ate1−/− mouse EF cells that had
been treated with both TNFα and a subtoxic level of cyclohexi-
mide, a regimen that induces apoptosis in EF cells (33) (Figs. S3D
andE and S5B). In addition, full-length RIPK1 was decreased but
retained in both Ate1−/− and WT EF cells treated with TNFα-
cycloheximide (Figs. S3 D and E and S5B).
The TNFα-induced loss of RIPK1 from the lungs and pan-
creases of ATE1-deﬁcient mice (Fig. S4A) was accompanied by
an approximately fourfold increase of apoptotic (TUNEL-posi-
tive) cells in these tissues compared with ATE1-containing mice
(Fig. 1E and Fig. S4B). The complete or nearly complete dis-
appearance of RIPK1 from the pancreases, lungs, and spleens of
TNFα-treated ATE1-deﬁcient (but not ATE1-containing) mice
(Fig. S4A) suggested that most ATE1-deﬁcient cells in thus af-
fected tissues may become TUNEL-positive if examined signiﬁ-
cantly later than 12 h after TNFα treatment. Such a test would be
a technically difﬁcult proposition, given the increased toxicity of
TNFα to ATE1-deﬁcient mice. Even by 12 h after TNFα treat-
ment, the majority of acinar cells in the pancreases of ATE1-
deﬁcient (but not ATE1-containing) mice exhibited signs of
damage, an alteration that may be causally linked to the also
observed decrease of tubulin in the pancreases of TNFα-treated
Ate1-deﬁcient mice (Fig. S4A, lanes 16 and 18 compared with
lane 13; each lane corresponds to a sample from an individual
mouse). The positive feedback that involves RIPK1, the Cys-
RIPK1 fragment, and caspase-8 (33–35) is likely to play a role in
the striking effect of TNFα on the levels of RIPK1 in the absence
of Nt-arginylation (Fig. S4A). A detailed understanding of this
robustly reproducible all-or-none effect, which is likely to involve
more than one RIPK1 circuit, is the subject of future studies.
Caspases Can Down-Regulate the Arg/N-End Rule Pathway.Given the
observed antiapoptotic activity of the Arg/N-end rule pathway,
might there be a mutual suppression between this pathway and
proapoptotic effectors such as, for example, activated caspases?
To address this possibility, we measured the Nt-arginylation of
added Glu-lactalbumin (an Nt-arginylation reporter) in extracts
from mouse NIH 3T3 cells that had been treated either with
TNFα alone (50 ng/mL), a subtoxic level of cycloheximide (10
μg/mL), or both, the latter treatment being an apoptosis-in-
ducing one (33). Treatments of cells with cycloheximide alone
reproducibly increased Nt-arginylation approximately twofold
after 24 h (Fig. S5A). This effect may be caused by a down-
regulation, through a cycloheximide-mediated decrease in
translation, of a short-lived repressor of the ATE1 R-transferase.
In contrast, the treatment with cycloheximide plus TNFα de-
creased Nt-arginylation by ∼2.3-fold after 24 h, which is in
agreement with the results of ATE1-speciﬁc immunoblotting of
cell extracts that indicated the in vivo degradation of ATE1
during apoptosis (Fig. S5 A and B). ATE1 and E3 N-recognins,
such as UBR1 (Fig. 1A), contain caspase cleavage sites (Fig.
S5C). Indeed, puriﬁed mouse ATE1 was found to be both
cleaved and functionally inactivated by added caspase-8 (Fig. 4B
and Fig. S5D). The UBR1 E3 N-recognin in an extract from
mouse 3T3 cells was also cleaved by caspase-8 and/or other ac-
tivated caspases in the extract. These cleavages, which remain to
be examined for their effects on UBR1 activity, could be
inhibited by a pan-caspase inhibitor (Fig. S5E). In sum, there is
a mutual suppression between the Arg/N-end rule pathway and
proapoptotic signaling.
Discussion
The previously identiﬁed proapoptotic protein fragments Cys-
RIPK1, Cys-TRAF1, Asp-BRCA1, Leu-LIMK1, Tyr-NEDD9,
Arg-BID, Asp-BCLXL, Arg-BIMEL, Asp-EPHA4, and Tyr-MET
(Figs. S1 and S2) are produced in cells by activated caspases
(eight fragments) or activated calpains (two fragments). They
were shown here to be short-lived substrates of the Arg/N-end
rule pathway (Figs. 2, 3, and 4 and Figs. S1 and S2). The com-
plete set of proapoptotic fragments that are also short-lived Arg/
N-end rule substrates is almost certainly larger than the 10
substrates identiﬁed in the present study, because several other
previously described proapoptotic fragments remain to be ex-
amined for their degradation by the Arg/N-end rule pathway
(Fig. S1). In addition, more of such fragments are likely to be
identiﬁed in the future. By destroying these fragments, the Arg/
N-end rule pathway down-regulates their proapoptotic activities
and thereby inhibits reactions that lead to cell death.
We also found that the metabolic stabilization of a speciﬁc
proapoptotic fragment such as Cys-RIPK1 (through its conver-
sion to the otherwise identical Val-RIPK1 fragment) greatly
augments the activation of the apoptosis-inducing effector cas-
pase-3 in human cells as well as their eventual apoptosis (Fig. 4 A
and B), indicating that the antiapoptotic activity of the Arg/
N-end rule pathway is likely to be a signiﬁcant contributor to the
physiological control of apoptosis. This conclusion is also sup-
ported by conceptually independent evidence provided by Arg/
N-end rule mutants. Mouse cells in which the Arg/N-end rule
pathway was weakened in two entirely different ways (through
the ablation of either Nt-arginylation or two of four N-recognins)














were hypersensitive to apoptosis induced by TNFα, staur-
osporine, or UV irradiation (Fig. 1 B–E and Figs. S3C and S4B).
This ﬁnding would be expected if the Arg/N-end rule pathway is
a repressor of apoptosis at least in part through its ability to
destroy proapoptotic fragments (Figs. 2 and 3). It remains to be
determined whether the antiapoptotic function of the Arg/N-end
rule pathway is conﬁned to this mechanism or involves additional
processes as well.
As described in Results, the destabilizing nature of N-terminal
residues of the proapoptotic fragments (these residues are at P1′
positions in the cleavage sites of the corresponding precursor
proteins) is fully conserved among vertebrates, either through
direct conservation of P1′ identities (Figs. S1 and S2) or, in the
case of BRCA1, despite a drift of the exact identity of the P1′
residue. In the latter case, the identity of the P1′ residue changed
during the evolution of mammals but remained destabilizing in
the Arg/N-end rule pathway (Fig. S2C). A constraint of this kind
would be expected if a short in vivo half-life of a proapoptotic
fragment (rather than the exact identity of a P1′ residue in
a protein precursor) was a ﬁtness-increasing property of this
fragment maintained by selection during evolution. More than
90% of the mapped caspase cleavage sites in cellular proteins
contain, at their P1′ positions, small residues such as Gly, Ser,
Thr, and Ala (4, 8), which are not recognized by the Arg/N-end
rule pathway (Fig. 1A). Therefore, destabilizing P1′ residues in
the precursors of proapoptotic fragments (let alone the evolu-
tionary conservation of these residues) (Figs. S1 and S2) would
not be expected on a priori grounds, given the preponderance of
smaller P1′ residues in caspase substrates at large (4, 8). In sum,
the evolutionary patterns of destabilizing P1′ residues (future N-
terminal residues) in the precursors of proapoptotic fragments,
including the retention of their destabilizing activity despite
a drift of their identity (Fig. S2C), strongly suggest that the
metabolic instability of proapoptotic fragments is their func-
tionally important attribute.
Protease-generated proapoptotic fragments likely act as
components of positive feedbacks that amplify speciﬁc aspects of
apoptosis, including caspase activation. For most proapoptotic
fragments (Fig. S1), the mechanisms of their previously shown
proapoptotic activity are either unknown or surmised, at best, in
general terms. Cys-RIPK1 (Figs. 2 B and C and 3K and Figs. S1,
S2A, S3 A, B, D, and E, and S4A) is a partial exception. This
fragment can be produced from RIPK1 by caspase-8 and other
caspases (33–36). Full-length RIPK1 is a conditionally short-
lived kinase and a multifunctional regulator of not only apoptosis
but also programmed necrosis (necroptosis) and antiviral
responses that do not involve cell death (6, 33). The caspase-
generated Cys-RIPK1 fragment (Fig. S2A) promotes apoptosis,
at least in part, by accelerating the activation of caspase-8, which
cleaves RIPK1 to generate more Cys-RIPK1. The result is a
proapoptotic positive feedback (33–35).
Previous work has shown that a Drosophila IAP protein
(DIAP1) is cleaved by the DRICE caspase, resulting in the Asn21-
DIAP1 fragment that is degraded by the Arg/N-end rule pathway
(37). However, in contrast to proapoptotic fragments (Fig. S1),
both full-length DIAP1 and the Asn21-DIAP1 fragment are
antiapoptotic proteins. The biological role of the degradation
of Asn21-DIAP1 by the Arg/N-end rule pathway remains to
be understood.
We found that the ATE1 R-transferase is degraded in apo-
ptotic cells, that caspases can cleave both ATE1 and the UBR1
N-recognin, and that these cleavages can functionally inactivate
at least R-transferase, suggesting a dynamic of mutual suppres-
sion between the Arg/N-end rule pathway and proapoptotic
signaling (Figs. 1A and 4B and Fig. S5). Biological ramiﬁcations
of this antagonism are the subject of future studies. A parsimo-
nious interpretation is that caspase-mediated inhibition of the
Arg/N-end rule pathway would increase late in apoptosis, when
a robust proapoptotic signaling begins to succeed in outplaying
the antiapoptotic activity of the Arg/N-end rule pathway and
other antiapoptotic circuits strongly enough for proapoptotic
processes to reach the point of no return.
For clarity, the working model of the layer of antiapoptotic
control described in the present work focuses solely on apoptosis
vis á vis the Arg/N-end rule pathway (Fig. 5). Our results indicate
that the Arg/N-end rule pathway inhibits apoptosis at least in
part through selective degradation of proapoptotic fragments.
In conjunction with other apoptosis-suppressing circuits, the Arg/
N-end rule pathway contributes to thresholds that prevent a
transient or otherwise weak proapoptotic signal from reaching the
point of commitment to apoptosis. Other antiapoptotic effectors
include IAP proteins and the NF-κB transcriptional regulon (5, 15,
16). IAPs inhibit and/or degrade activated caspases, whereas the
Arg/N-end rule pathway destroys speciﬁc proapoptotic fragments
other than caspases (Fig. 5 and Fig. S1).
This understanding (Fig. 5) both accounts for and is in
agreement with previous ﬁndings. Speciﬁcally, spermatocytes of
mice that lack either the UBR2 N-recognin or the ATE1 R-
Fig. 5. The Arg/N-end rule pathway as a regulator of apoptosis. Key aspects
of this working model are the demonstrated degradation of proapoptotic
Arg/N-end rule substrates (Asp-BRCA1, Leu-LIMK1, Tyr-NEDD9, Arg-BID, Asp-
BCLXL, Arg-BIMEL, Asp-EPHA4, Tyr-MET, Cys-TRAF1, and Cys-RIPK1) by the
Arg/N-end rule pathway and the counteracting inhibition of this pathway by
activated caspases. In conjunction with other antiapoptotic circuits, the se-
lective degradation of proapoptotic protein fragments by the Arg/N-end
rule pathway acts to generate thresholds that prevent a transient or oth-
erwise weak proapoptotic signal from reaching the point of commitment
to apoptosis.
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transferase undergo apoptosis during meiosis, resulting in male
infertility (30, 38). Johanson–Blizzard syndrome (JBS) is caused
by inactivating mutations in both copies of UBR1, which encodes
an N-recognin (Fig. 1A) (23, 39). Clinical features of JBS are
consistent with our ﬁnding that even a partial ablation of the
Arg/N-end rule pathway sensitizes cells to apoptosis (Fig. 1 B–E
and Fig. S3C). For example, nasal wing aplasia (near-absence of
nostrils) in JBS patients is likely to result from apoptosis of cells
that normally form nasal wings. Insufﬁciency and inﬂammation
of exocrine pancreas in JBS are likely to be caused by apoptosis
of acinar cells (17, 23). The antiapoptotic activity of the Arg/
N-end rule pathway suggests that its up-regulation may facilitate
malignant phenotypes in mammalian cell lineages. Indeed, the
gene for UBR5 (EDD), one of N-recognins (Fig. 1A), is often
ampliﬁed in ovarian carcinoma, and it is an adverse prognostic
factor in this disease (40).
Regulation of apoptosis and its derangements in cancer, neu-
rodegenerative syndromes, metabolic disorders, andmalfunctions
of immunity are among the hallmarks of these diseases. Our
results have shown that the Arg/N-end rule pathway is a mecha-
nistically speciﬁc repressor of programmed cell death (Fig. 5).
This discovery may allow a modulation of apoptosis in clinically
relevant settings by altering the activity of the Arg/N-end rule
pathway. The targeting of some N-degrons in proapoptotic pro-
tein fragments involves not only speciﬁc Ub ligases (N-recognins)
but also preceding steps, including the effects of nitric oxide and
oxygen, the activity of the NTAN1 and NTAQ1 Nt-amidases, and
the activity of the ATE1 R-transferase (Fig. 1A and Fig. S1) (17).
The resulting possibility of augmenting or inhibiting speciﬁc
branches of the Arg/N-end rule pathway opens up pharmaceutical
opportunities to alter the properties of apoptotic circuits.
Materials and Methods
Mutants in the Arg/N-End Rule Pathway. Mouse strains included conditionally
ATE1-deﬁcient Ate1ﬂox/-, CaggCreER mice, in which the remaining copy of
Ate1 could be inactivated through a transient activation of Cre recombinase
(30). Untransformed cells as well as cell lines included T-Rex-293 human cell
lines stably expressing test proteins; primary (precrisis) mouse Ate1−/− EF cells
and established cell lines; and a Ubr1−/− Ubr2−/− EF cell line. They are de-
scribed in SI Materials and Methods.
Pulse-Chase, Caspase, Apoptosis, Arginylation, and Immunoblotting Assays.
Assays with the transcription/translation-enabled reticulocyte extract, in vivo
pulse-chase assays, and other technical details of this study are described in SI
Materials and Methods.
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